Subnavigation

• Initiative for vaccine research
• Vaccine research and development
• Implementation research
• Advisory committees
• Links
• About

Bacterial Infections

References

References

References

[1] Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009;360:244-56.

[2] Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offit P, editors. Vaccines 5th ed. Philadelphia: Saunders Elsevier, 2008: 399-434.

[3] Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-year experience. Wkly Epidemiol Rec 2005;80:313-20.

[4] Cartwright K, Noah N, Peltola H. Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. Vaccine 2001;19:4347-56.

[5] Cuevas LE, Jeanne I, Molesworth A, Bell M, Savory EC, Connor SJ, et al. Risk mapping and early warning systems for the control of meningitis in Africa. Vaccine 2007;25 Suppl 1:A12-7.

[6] Molesworth AM, Cuevas LE, Connor SJ, Morse AP, Thomson MC. Environmental risk and meningitis epidemics in Africa. Emerg Infect Dis 2003;9:1287-93.

[7] Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. Apmis 1998;106:505-25.

[8] Wang JF, Caugant DA, Li X, Hu X, Poolman JT, Crowe BA, et al. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect Immun 1992;60:5267-82.

[9] Guibourdenche M, Hoiby EA, Riou JY, Varaine F, Joguet C, Caugant DA. Epidemics of serogroup A Neisseria meningitidis of subgroup III in Africa, 1989-94. Epidemiol Infect 1996;116:115-20.

[10] Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999;180:1894-901.

[11] Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J Paediatr Child Health 2001;37:S13-9.

[12] Brandtzaeg P, van Deuren M. Meningococcal infections at the start of the 21st century. Adv Pediatr 2005;52:129-62.

[13] Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998;95:3140-5.

[14] Kriz P, Kalmusova J, Felsberg J. Multilocus sequence typing of Neisseria meningitidis directly from cerebrospinal fluid. Epidemiol Infect 2002;128:157-60.

[15] Taha MK, Alonso JM. Molecular epidemiology of infectious diseases: the example of meningococcal disease. Res Microbiol 2008;159:62-6.

[16] Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006;19:142-64.

[17] Claus H, Maiden MC, Wilson DJ, McCarthy ND, Jolley KA, Urwin R, et al. Genetic analysis of meningococci carried by children and young adults. J Infect Dis 2005;191:1263-71.

[18] Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006;177:501-10.

[19] Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006;176:7566-75.

[20] Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 2006;24:4692-700.

[21] Initiative for Vaccine Research (WHO). Proceedings 7th Global Vaccine Research Forum. Bangkok; 2006.

[22] Teyssou R, Muros-Le Rouzic E. Meningitis epidemics in Africa: a brief overview. Vaccine 2007;25 Suppl 1:A3-7.

[23] LaForce FM, Konde K, Viviani S, Preziosi MP. The Meningitis Vaccine Project. Vaccine 2007;25 Suppl 1:A97-100.

[24] Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001;19:2688-91.

[25] Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med 2004;10:1177-85.

[26] Gotschlich EC, Liu TY, Artenstein MS. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med 1969;129:1349-65.

[27] Al-Mazrou Y, Khalil M, Borrow R, Balmer P, Bramwell J, Lal G, et al. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. Infect Immun 2005;73:2932-9.

[28] O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007;7:597-606.

[29] Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20 Suppl 1:S58-67.

[30] De Wals P, Nguyen VH, Erickson LJ, Guay M, Drapeau J, St-Laurent J. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine 2004;22:1233-40.

[31] Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003;326:365-6.

[32] Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197:737-43.

[33] Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364:365-7.

[34] Snape MD, Kelly DF, Lewis S, Banner C, Kibwana L, Moore CE, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008;336:1487-91.

[35] Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004;23:824-8.

[36] Pace D, Snape M, Westcar S, Oluwalana C, Yu LM, Begg N, et al. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Arch Dis Child 2008;93:963-70.

[37] Gatchalian S, Palestroque E, De Vleeschauwer I, Han HH, Poolman J, Schuerman L, et al. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. Int J Infect Dis 2008;12:278-88.

[38] Jodar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 2003;361:1902-4.

[39] Roberts L. Infectious disease. An ill wind, bringing meningitis. Science 2008;320:1710-5.

[40] Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Preziosi MP, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007;25 Suppl 1:A101-7.

[41] Initiative for Vaccine Research (WHO). Proceedings of the 9th Global Vaccine Research Forum. Paris 2008.

[42] Griffiss JM, Yamasaki R, Estabrook M, Kim JJ. Meningococcal molecular mimicry and the search for an ideal vaccine. Trans R Soc Trop Med Hyg 1991;85 Suppl 1:32-6.

[43] Feiring B, Fuglesang J, Oster P, Naess LM, Helland OS, Tilman S, et al. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol 2006;13:790-6.

[44] Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005;23:2191-6.

[45] Jackson CM, Lennon DR, Sotutu VT, Yan J, Stewart JM, Reid S, et al. Phase II Meningococcal B Vesicle Vaccine Trial in New Zealand Infants. Arch Dis Child 2008.

[46] O'Hallahan J, Lennon D, Oster P. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J 2004;23:S293-8.

[47] McNicholas A, Galloway Y, Stehr-Green P, Reid S, Radke S, Sexton K, et al. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Hum Vaccin 2007;3:196-204.

[48] Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007;25:3075-9.

[49] Padron FS, Huergo CC, Gil VC, Diaz EMF, Valdespino IEC, Gotera NG. Cuban meningococcal BC vaccine: Experiences and contributions from 20 years of application. MEDICC Review 2007;9:16-22.

[50] Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999;281:1520-7.

[51] Morley SL, Cole MJ, Ison CA, Camaraza MA, Sotolongo F, Anwar N, et al. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr Infect Dis J 2001;20:1054-61.

[52] Perrett KP, Pollard AJ. Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opin Biol Ther 2005;5:1611-25.

[53] Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum Vaccin 2007;3:290-4.

[54] van der Ley P, van der Biezen J, Poolman JT. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 1995;13:401-7.

[55] Claassen I, Meylis J, van der Ley P, Peeters C, Brons H, Robert J, et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996;14:1001-8.

[56] Peeters CC, Rumke HC, Sundermann LC, Rouppe van der Voort EM, Meulenbelt J, Schuller M, et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 1996;14:1009-15.<>
B [57] Cartwright K, Morris R, Rumke H, Fox A, Borrow R, Begg N, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999;17:2612-9.

[58] Oliver KJ, Reddin KM, Bracegirdle P, Hudson MJ, Borrow R, Feavers IM, et al. Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 2002;70:3621-6.

[59] Gorringe AR. Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease? Expert Rev Vaccines 2005;4:373-9.

[60] Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000;287:1816-20.

[61] Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000;3:445-50.

[62] Capecchi B, Serruto D, Adu-Bobie J, Rappuoli R, Pizza M. The genome revolution in vaccine research. Curr Issues Mol Biol 2004;6:17-27.

[63] Mora M, Donati C, Medini D, Covacci A, Rappuoli R. Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach. Curr Opin Microbiol 2006;9:532-6.

[64] Grifantini R, Bartolini E, Muzzi A, Draghi M, Frigimelica E, Berger J, et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol 2002;20:914-21.

[65] Danzig L. Meningococcal vaccines. Pediatr Infect Dis J 2004;23:S285-92.

[66] Sun Y, Li Y, Exley RM, Winterbotham M, Ison C, Smith H, et al. Identification of novel antigens that protect against systemic meningococcal infection. Vaccine 2005;23:4136-41.

[67] Hou VC, Koeberling O, Welsch JA, Granoff DM. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis 2005;192:580-90.

[68] Giuliani MM, Santini L, Brunelli B, Biolchi A, Arico B, Di Marcello F, et al. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun 2005;73:1151-60.

[69] Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003;188:1730-40.

[70] Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Arico B, Capecchi B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002;195:1445-54.

[71] Capecchi B, Adu-Bobie J, Di Marcello F, Ciucchi L, Masignani V, Taddei A, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 2005;55:687-98.

[72] Beernink PT, Leipus A, Granoff DM. Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol 2006;13:758-63.

[73] Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 2007;195:1472-9.

[74] Beernink PT, Granoff DM. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun 2008;76:2568-75.

[75] Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006;103:10834-9.

[76] Jacobsson S, Hedberg ST, Molling P, Unemo M, Comanducci M, Rappuoli R, et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 2009;27:1579-84.

[77] Price AA. Meningococcal vaccines. Curr Pharm Des 2007;13:2009-14.

[78] Daum RS. Staphylocossus aureus vaccines. In: Plotkin SA, Orenstein WA, Offit P, editors. Vaccines 5th ed. Philadelphia: Saunders Elsevier, 2008: 1307-15.

[79] Nickerson EK, Hongsuwan M, Limmathurotsakul D, Wuthiekanun V, Shah KR, Srisomang P, et al. Staphylococcus aureus bacteraemia in a tropical setting: patient outcome and impact of antibiotic resistance. PLoS ONE 2009;4:e4308.

[80] Bashore TM, Cabell C, Fowler V, Jr. Update on infective endocarditis. Curr Probl Cardiol 2006;31:274-352.

[81] Frank AL, Marcinak JF, Mangat PD, Schreckenberger PC. Increase in community-acquired methicillin-resistant Staphylococcus aureus in children. Clin Infect Dis 1999;29:935-6.

[82] Gorak EJ, Yamada SM, Brown JD. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999;29:797-800.

[83] Moran GJ, Mount J. Update on emerging infections: news from the Centers for Disease Control and Prevention. Ann Emerg Med 2003;41:148-51.

[84] Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178-82.

[85] Middleton JR. Staphylococcus aureus antigens and challenges in vaccine development. Expert Rev Vaccines 2008;7:805-15.

[86] Sompolinsky D, Samra Z, Karakawa WW, Vann WF, Schneerson R, Malik Z. Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. J Clin Microbiol 1985;22:828-34.

[87] O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 2004;17:218-34.

[88] Poutrel B, Sutra L. Type 5 and 8 capsular polysaccharides are expressed by Staphylococcus aureus isolates from rabbits, poultry, pigs, and horses. J Clin Microbiol 1993;31:467-9.

[89] Tollersrud T, Kenny K, Reitz AJ, Jr., Lee JC. Genetic and serologic evaluation of capsule production by bovine mammary isolates of Staphylococcus aureus and other Staphylococcus spp. from Europe and the United States. J Clin Microbiol 2000;38:2998-3003.

[90] Cunnion KM, Lee JC, Frank MM. Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect Immun 2001;69:6796-803.

[91] Nemeth J, Lee JC. Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis. Infect Immun 1995;63:375-80.

[92] Bhakdi S, Tranum-Jensen J. Alpha-toxin of Staphylococcus aureus. Microbiol Rev 1991;55:733-51.

[93] Cheung AI, Projan SJ, Edelstein RE, Fischetti VA. Cloning, expression, and nucleotide sequence of a Staphylococcus aureus gene (fbpA) encoding a fibrinogen-binding protein. Infect Immun 1995;63:1914-20.

[94] McDevitt D, Francois P, Vaudaux P, Foster TJ. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol Microbiol 1994;11:237-48.

[95] Fattom A, Schneerson R, Szu SC, Vann WF, Shiloach J, Karakawa WW, et al. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun 1990;58:2367-74.

[96] Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, et al. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 1993;61:1023-32.

[97] Fattom AI, Sarwar J, Ortiz A, Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 1996;64:1659-65.

[98] Lee JC, Park JS, Shepherd SE, Carey V, Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 1997;65:4146-51.

[99] Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002;346:491-6.

[100]Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine 2004;22:880-7.

[101]Shinefield HR. Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible? Vaccine 2006;24 Suppl 2:S2-65-9.

[102]Schaffer AC, Lee JC. Vaccination and passive immunisation against Staphylococcus aureus. Int J Antimicrob Agents 2008;32 Suppl 1:S71-8.

[103]Maira-Litran T, Kropec A, Goldmann DA, Pier GB. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun 2005;73:6752-62.

[104]McKenney D, Pouliot KL, Wang Y, Murthy V, Ulrich M, Doring G, et al. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 1999;284:1523-7.

[105]Tuchscherr LP, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect Immun 2008;76:5738-44.

[106]Nanra JS, Timofeyeva Y, Buitrago SM, Sellman BR, Dilts DA, Fink P, et al. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: Implications for vaccine design. Vaccine 2009.

[107]Schaffer AC, Solinga RM, Cocchiaro J, Portoles M, Kiser KB, Risley A, et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun 2006;74:2145-53.

[108]Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, McNeely T, et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006;74:2215-23.

[109]Arrecubieta C, Matsunaga I, Asai T, Naka Y, Deng MC, Lowy FD. Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J Infect Dis 2008;198:571-5.

[110]Medini D, Donati C, Tettelin H, Masignani V, Rappuoli R. The microbial pan-genome. Curr Opin Genet Dev 2005;15:589-94.

[111]Serruto D, Rappuoli R. Post-genomic vaccine development. FEBS Lett 2006;580:2985-92.

[112]Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 2006;103:16942-7.

[113]Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000;13:470-511.

[114]Pfoh E, Wessels MR, Goldmann D, Lee GM. Burden and economic cost of group A streptococcal pharyngitis. Pediatrics 2008;121:229-34.

[115]Bisno AL. Acute pharyngitis: etiology and diagnosis. Pediatrics 1996;97:949-54.

[116]Linder JA, Bates DW, Lee GM, Finkelstein JA. Antibiotic treatment of children with sore throat. JAMA 2005;294:2315-22.

[117]Adderson EE, Shikhman AR, Ward KE, Cunningham MW. Molecular analysis of polyreactive monoclonal antibodies from rheumatic carditis: human anti-N-acetylglucosamine/anti-myosin antibody V region genes. J Immunol 1998;161:2020-31.

[118]Dale JB, Beachey EH. Sequence of myosin-crossreactive epitopes of streptococcal M protein. J Exp Med 1986;164:1785-90.

[119]Batzloff MR, Sriprakash KS, Good MF. Vaccine development for group A streptococcus infections and associated disease. Curr Drug Targets 2004;5:57-69.

[120]WHO programme for the prevention of rheumatic fever/rheumatic heart disease in 16 developing countries: report from Phase I (1986-90). WHO Cardiovascular Diseases Unit and principal investigators. Bull World Health Organ 1992;70:213-8.

[121]Brandt ER, Teh T, Relf WA, Hobb RI, Good MF. Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci. Infect Immun 2000;68:6587-94.

[122]
[123]O'Brien KL, Beall B, Barrett NL, Cieslak PR, Reingold A, Farley MM, et al. Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin Infect Dis 2002;35:268-76.

[124]O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007;45:853-62.

[125]Siljander T, Toropainen M, Muotiala A, Hoe NP, Musser JM, Vuopio-Varkila J. emm typing of invasive T28 group A streptococci, 1995-2004, Finland. J Med Microbiol 2006;55:1701-6.

[126]Lamagni TL, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B, et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2008;46:2359-67.

[127]Cockerill FR, 3rd, MacDonald KL, Thompson RL, Roberson F, Kohner PC, Besser-Wiek J, et al. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA 1997;277:38-43.

[128]Haukness HA, Tanz RR, Thomson RB, Jr., Pierry DK, Kaplan EL, Beall B, et al. The heterogeneity of endemic community pediatric group a streptococcal pharyngeal isolates and their relationship to invasive isolates. J Infect Dis 2002;185:915-20.

[129]Kotloff KL. Streptococcus group A vaccines. In: Plotkin SA, Orenstein WA, Offit P, editors. Vaccines, 5th ed. Philadelphia: Saunders Elsevier, 2008: 1317-25.

[130]Mora M, Bensi G, Capo S, Falugi F, Zingaretti C, Manetti AG, et al. Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci U S A 2005;102:15641-6.

[131]Falugi F, Zingaretti C, Pinto V, Mariani M, Amodeo L, Manetti AG, et al. Sequence variation in group A Streptococcus pili and association of pilus backbone types with lancefield T serotypes. J Infect Dis 2008;198:1834-41.

[132]Manetti AG, Zingaretti C, Falugi F, Capo S, Bombaci M, Bagnoli F, et al. Streptococcus pyogenes pili promote pharyngeal cell adhesion and biofilm formation. Mol Microbiol 2007;64:968-83.

[133]Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1989;2:285-314.

[134]Tanaka D, Gyobu Y, Kodama H, Isobe J, Hosorogi S, Hiramoto Y, et al. emm Typing of group A streptococcus clinical isolates: identification of dominant types for throat and skin isolates. Microbiol Immunol 2002;46:419-23.

[135]Sagar V, Kumar R, Ganguly NK, Chakraborti A. Comparative analysis of emm type pattern of Group A Streptococcus throat and skin isolates from India and their association with closely related SIC, a streptococcal virulence factor. BMC Microbiol 2008;8:150.

[136]Smeesters PR, Mardulyn P, Vergison A, Leplae R, Van Melderen L. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development. Vaccine 2008;26:5835-42.

[137]Ji Y, McLandsborough L, Kondagunta A, Cleary PP. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun 1996;64:503-10.

[138]Ji Y, Schnitzler N, DeMaster E, Cleary P. Impact of M49, Mrp, Enn, and C5a peptidase proteins on colonization of the mouse oral mucosa by Streptococcus pyogenes. Infect Immun 1998;66:5399-405.

[139]Gillen CM, Courtney HS, Schulze K, Rohde M, Wilson MR, Timmer AM, et al. Opacity factor activity and epithelial cell binding by the serum opacity factor protein of Streptococcus pyogenes are functionally discrete. J Biol Chem 2008;283:6359-66.

[140]Courtney HS, Dale JB, Hasty DI. Differential effects of the streptococcal fibronectin-binding protein, FBP54, on adhesion of group A streptococci to human buccal cells and HEp-2 tissue culture cells. Infect Immun 1996;64:2415-9.

[141]Stalhammar-Carlemalm M, Areschoug T, Larsson C, Lindahl G. The R28 protein of Streptococcus pyogenes is related to several group B streptococcal surface proteins, confers protective immunity and promotes binding to human epithelial cells. Mol Microbiol 1999;33:208-19.

[142]Bisno AL, Brito MO, Collins CM. Molecular basis of group A streptococcal virulence. Lancet Infect Dis 2003;3:191-200.

[143]Pahlman LI, Morgelin M, Eckert J, Johansson L, Russell W, Riesbeck K, et al. Streptococcal M protein: a multipotent and powerful inducer of inflammation. J Immunol 2006;177:1221-8.

[144]Hasty DL, Ofek I, Courtney HS, Doyle RJ. Multiple adhesins of streptococci. Infect Immun 1992;60:2147-52.

[145]Liu M, Zhu H, Zhang J, Lei B. Active and passive immunizations with the streptococcal esterase Sse protect mice against subcutaneous infection with group A streptococci. Infect Immun 2007;75:3651-7.

[146]Olive C, Moyle PM, Toth I. Towards the development of a broadly protective group A streptococcal vaccine based on the Lipid-Core Peptide system. Curr Med Chem 2007;14:2976-88.

[147]Massell BF, Honikman LH, Amezcua J. Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA 1969;207:1115-9.

[148]McMillan DJ, Chhatwal GS. Prospects for a group A streptococcal vaccine. Curr Opin Mol Ther 2005;7:11-6.

[149]Shaila MS, Nayak R, Prakash SS, Georgousakis M, Brandt E, McMillan DJ, et al. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles. Vaccine 2007;25:3567-73.

[150]Yoonim N, Olive C, Pruksachatkunakorn C, Pruksakorn S. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population. BMC Microbiol 2006;6:71.

[151]Batzloff MR, Hartas J, Zeng W, Jackson DC, Good MF. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J Infect Dis 2006;194:325-30.

[152]Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, et al. Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults: phase 1 trial. JAMA 2004;292:709-15.

[153]McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005;41:1114-22.

[154]Dale JB. Current status of group A streptococcal vaccine development. Adv Exp Med Biol 2008;609:53-63.

[155]Batzloff MR, Pandey M, Olive C, Good MF. Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease. Immunol Res 2006;35:233-48.

[156]Horvath A, Olive C, Karpati L, Sun HK, Good M, Toth I. Toward the development of a synthetic group A streptococcal vaccine of high purity and broad protective coverage. J Med Chem 2004;47:4100-4.

[157]Olive C, Batzloff M, Horvath A, Clair T, Yarwood P, Toth I, et al. Group A streptococcal vaccine delivery by immunization with a self-adjuvanting M protein-based lipid core peptide construct. Indian J Med Res 2004;119 Suppl:88-94.

[158]Olive C, Hsien K, Horvath A, Clair T, Yarwood P, Toth I, et al. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. Vaccine 2005;23:2298-303.

[159]Olive C, Ho MF, Dyer J, Lincoln D, Barozzi N, Toth I, et al. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus. J Infect Dis 2006;193:1666-76.

[160]Olive C, Sun HK, Ho MF, Dyer J, Horvath A, Toth I, et al. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. J Infect Dis 2006;194:316-24.

[161]Dey N, McMillan DJ, Yarwood PJ, Joshi RM, Kumar R, Good MF, et al. High diversity of group A Streptococcal emm types in an Indian community: the need to tailor multivalent vaccines. Clin Infect Dis 2005;40:46-51.

[162]Abdissa A, Asrat D, Kronvall G, Shittu B, Achiko D, Zeidan M, et al. High diversity of group A streptococcal emm types among healthy schoolchildren in Ethiopia. Clin Infect Dis 2006;42:1362-7.

[163]Park HS, Cleary PP. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun 2005;73:7878-86.

[164]Shet A, Kaplan EL, Johnson DR, Cleary PP. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. J Infect Dis 2003;188:809-17.

[165]Schulze K, Medina E, Chhatwal GS, Guzman CA. Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectin-binding domain of the SfbI protein. Vaccine 2003;21:1958-64.

[166]Kawabata S, Kunitomo E, Terao Y, Nakagawa I, Kikuchi K, Totsuka K, et al. Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun 2001;69:924-30.

[167]Schulze K, Olive C, Ebensen T, Guzman CA. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes. Vaccine 2006;24:6088-95.

[168]Roggiani M, Stoehr JA, Olmsted SB, Matsuka YV, Pillai S, Ohlendorf DH, et al. Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect Immun 2000;68:5011-7.

[169]McCormick JK, Tripp TJ, Olmsted SB, Matsuka YV, Gahr PJ, Ohlendorf DH, et al. Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome. J Immunol 2000;165:2306-12.

[170]Okamoto S, Tamura Y, Terao Y, Hamada S, Kawabata S. Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group A Streptococcus challenge in mice. Vaccine 2005;23:4852-9.

[171]Sabharwal H, Michon F, Nelson D, Dong W, Fuchs K, Manjarrez RC, et al. Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. J Infect Dis 2006;193:129-35.

[172]Lei B, Liu M, Chesney GL, Musser JM. Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins. J Infect Dis 2004;189:79-89.

[173]Rodriguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, Mora M, et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006;24:191-7.

[174]Zhang S, Green NM, Sitkiewicz I, Lefebvre RB, Musser JM. Identification and characterization of an antigen I/II family protein produced by group A Streptococcus. Infect Immun 2006;74:4200-13.

[175]Lei B, Mackie S, Lukomski S, Musser JM. Identification and immunogenicity of group A Streptococcus culture supernatant proteins. Infect Immun 2000;68:6807-18.

[176]Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000;342:15-20.

[177]Diminishing racial disparities in early-onset neonatal group B streptococcal disease--United States, 2000-2003. MMWR Morb Mortal Wkly Rep 2004;53:502-5.

[178]Gibbs RS, Schrag S, Schuchat A. Perinatal infections due to group B streptococci. Obstet Gynecol 2004;104:1062-76.

[179]Jordan HT, Farley MM, Craig A, Mohle-Boetani J, Harrison LH, Petit S, et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J 2008;27:1057-64.

[180]Farley MM. Group B streptococcal disease in nonpregnant adults. Clin Infect Dis 2001;33:556-61.

[181]Palazzi DL, Rench MA, Edwards MS, Baker CJ. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. J Infect Dis 2004;190:558-64.

[182]WLWfP_InkvMmGL Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults. Clin Infect Dis 2005;41:839-47.

[183]Johri AK, Paoletti LC, Glaser P, Dua M, Sharma PK, Grandi G, et al. Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol 2006;4:932-42.

[184]Healy CM, Baker CJ. Streptococcus group B vaccines. In: Plotkin SA, Orenstein WA, Offit P, editors. Vaccines 5th ed. Philadelphia: Saunders Elsevier, 2008: 1327-33.

[185]Edwards MS. Group B streptococcal conjugate vaccine: a timely concept for which the time has come. Hum Vaccin 2008;4:444-8.

[186]Baker CJ, Edwards MS. Group B streptococcal conjugate vaccines. Arch Dis Child 2003;88:375-8.

[187]Madoff LC, Paoletti LC, Tai JY, Kasper DL. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. J Clin Invest 1994;94:286-92.

[188]Paoletti LC, Pinel J, Johnson KD, Reinap B, Ross RA, Kasper DL. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII. J Infect Dis 1999;180:892-5.

[189]Paoletti LC, Peterson DL, Legmann R, Collier RJ. Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen. Vaccine 2001;20:370-6.

[190]Paoletti LC, Kasper DL. Glycoconjugate vaccines to prevent group B streptococcal infections. Expert Opin Biol Ther 2003;3:975-84.

[191]Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Carey VJ, Hickman ME, et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis 2000;182:1129-38.

[192]Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Edwards MS, Kasper DL. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis 2004;189:1103-12.

[193]Baker CJ, Rench MA, Paoletti LC, Edwards MS. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 2007;25:55-63.

[194]Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003;21:3468-72.

[195]Sinha A, Lieu TA, Paoletti LC, Weinstein MC, Platt R. The projected health benefits of maternal group B streptococcal vaccination in the era of chemoprophylaxis. Vaccine 2005;23:3187-95.

[196]Guttormsen HK, Liu Y, Paoletti LC. Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells. Hum Vaccin 2008;4:370-4.

[197]Larsson C, Lindroth M, Nordin P, Stalhammar-Carlemalm M, Lindahl G, Krantz I. Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection. Arch Dis Child Fetal Neonatal Ed 2006;91:F403-8.

[198]Madoff LC, Michel JL, Gong EW, Rodewald AK, Kasper DL. Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein. Infect Immun 1992;60:4989-94.

[199]Larsson C, Stalhammar-Carlemalm M, Lindahl G. Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha. Infect Immun 1996;64:3518-23.

[200]Stalhammar-Carlemalm M, Stenberg L, Lindahl G. Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections. J Exp Med 1993;177:1593-603.

[201]Stalhammar-Carlemalm M, Waldemarsson J, Johnsson E, Areschoug T, Lindahl G. Nonimmunodominant regions are effective as building blocks in a streptococcal fusion protein vaccine. Cell Host Microbe 2007;2:427-34.

[202]Brodeur BR, Boyer M, Charlebois I, Hamel J, Couture F, Rioux CR, et al. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infect Immun 2000;68:5610-8.

[203]Cheng Q, Carlson B, Pillai S, Eby R, Edwards L, Olmsted SB, et al. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect Immun 2001;69:2302-8.

[204]Santillan DA, Andracki ME, Hunter SK. Protective immunization in mice against group B streptococci using encapsulated C5a peptidase. Am J Obstet Gynecol 2008;198:114 e1-6.

[205]Yang HH, Madoff LC, Guttormsen HK, Liu YD, Paoletti LC. Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines. Infect Immun 2007;75:3455-61.

[206]Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M, et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 2005;309:148-50.

[207]Santi I, Pezzicoli A, Bosello M, Berti F, Mariani M, Telford JL, et al. Functional characterization of a newly identified group B streptococcus pullulanase eliciting antibodies able to prevent alpha-glucans degradation. PLoS ONE 2008;3:e3787.

[208]Lauer P, Rinaudo CD, Soriani M, Margarit I, Maione D, Rosini R, et al. Genome analysis reveals pili in Group B Streptococcus. Science 2005;309:105.

[209]Rosini R, Rinaudo CD, Soriani M, Lauer P, Mora M, Maione D, et al. Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. Mol Microbiol 2006;61:126-41.

[210]Buccato S, Maione D, Rinaudo CD, Volpini G, Taddei AR, Rosini R, et al. Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. J Infect Dis 2006;194:331-40.

[211] Margarit I, Rinaudo CD, Galeotti CL, Maione D, Ghezzo C, Buttazzoni E, et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 2009;199:108-15